Sotabase

Career

· Associate Group Leader, MIT Lincoln Laboratory2024–
· Assistant Group Leader, MIT Lincoln Laboratory2020–2024
· Technical Staff, MIT Lincoln Laboratory2015–2020
· Software Engineer, IBM Microelectronics2012–2015
· PhD in Materials Science and Engineering, Massachusetts Institute of Technology2012–
· Postdoctoral Researcher, MIT2012–2012
· BS in Materials Science and Engineering, University of Illinois at Urbana-Champaign

Publications (51)

Preclinical profile of a potent gamma-secretase inhibitor targeting notch signaling with in vivo efficacy and pharmacodynamic properties.
Cancer Research · 2009
190
cited
Antitumor activity of erlotinib (OSI-774, Tarceva) alone or in combination in human non-small cell lung cancer tumor xenograft models
Anti-Cancer Drugs · 2004
151
cited
In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials
Molecular Cancer Therapeutics · 2006
98
cited
Discovery of siRNA lipid nanoparticles to transfect suspension leukemia cells and provide in vivo delivery capability.
Molecular Therapy · 2014
60
cited
High tumor levels of IL6 and IL8 abrogate preclinical efficacy of the γ‐secretase inhibitor, RO4929097
Molecular Oncology · 2011
52
cited
Rhabdoid Tumor Growth is Inhibited by Flavopiridol
Clinical Cancer Research · 2008
47
cited
Therapeutically targeting cyclin D1 in primary tumors arising from loss of Ini1
Proceedings of the National Academy of Sciences of the United States of America · 2010
46
cited
RG7212 Anti-TWEAK mAb Inhibits Tumor Growth through Inhibition of Tumor Cell Proliferation and Survival Signaling and by Enhancing the Host Antitumor Immune Response
Clinical Cancer Research · 2013
32
cited
Loss-of-Function SCN5A Mutations Associated With Sinus Node Dysfunction, Atrial Arrhythmias, and Poor Pacemaker Capture
Circulation: Arrhythmia and Electrophysiology · 2015
27
cited
Antitumor activity of HER1/EGFR tyrosine kinase inhibitor erlotinib, alone and in combination with CPT-11 (irinotecan) in human colorectal cancer xenograft models
Cancer Chemotherapy and Pharmacology · 2007
25
cited
Blockade of VLA4 sensitizes leukemic and myeloma tumor cells to CD3 redirection in the bone marrow microenvironment
Blood Cancer Journal · 2020
24
cited
Potent inhibition of rhabdoid tumor cells by combination of flavopiridol and 4OH-tamoxifen
BMC Cancer · 2010
20
cited
The binding of human alloantibodies to recombinant glycophorin A
Transfusion · 1992
16
cited
Design and synthesis of 4-HPR derivatives for rhabdoid tumors.
Bioorganic & Medicinal Chemistry Letters · 2008
15
cited
Design, synthesis of novel peptidomimetic derivatives of 4-HPR for rhabdoid tumors.
Bioorganic & Medicinal Chemistry Letters · 2008
12
cited
In vitro activities of novel 4-HPR derivatives on a panel of rhabdoid and other tumor cell lines
Cancer Cell International · 2011
10
cited
Abstract 5567:In vivoadministration of the STING agonist, JNJ-67544412, leads to complete regression of established murine subcutaneous tumors
Immunology · 2020
9
cited
Abstract 5567A: JNJ-‘6196: A next generation STING agonist with potent preclinical activity by the IV route
2020
5
cited
Abstract 1101: Telomerase inhibitor imetelstat in combination with the BCL-2 inhibitor venetoclax enhances apoptosisin vitroand increases survivalin vivoin acute myeloid leukemia
2017
2
cited
Development of targeted therapies for rhabdoid tumors based on the functions of INI1/hSNF5 tumor suppressor
2010
2
cited
Sotabase
Melissa Smith | Researcher Profile | Sotabase | Sotabase